Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The amended agreement supports patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the expanded terms, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion is important because it moves blockchain-based health data management from a niche pharmaceutical application into broader healthcare settings, potentially giving patients more control over their medical data. By integrating Datavault AI’s technology, patients could monetize their health data or tokenize real-world assets like lab results or wearable device data. This aligns with trends in decentralized health data ownership and could disrupt traditional healthcare data silos.
Datavault AI’s platform, which includes its Acoustic Sciences and Data Sciences divisions, leverages Web 3.0 and high-performance computing for data perception, valuation and secure monetization. The company’s technology suite is customizable and offers AI- and machine-learning-based automation, third-party integration, and analytics. The partnership with DataMEDS leverages a behavioral healthcare patent portfolio that could enhance remote patient monitoring and population health management.
The global health and wellness market is expanding rapidly, and this agreement positions Datavault AI to capture a share of that growth. By enabling new patient-controlled data transaction models, the company could tap into the growing demand for personalized health data management. The amended licensing agreement also provides Datavault AI with a significant equity stake in DataMEDS, aligning incentives for long-term collaboration.
For more information, visit the press release at https://ibn.fm/vBAxH. Details about Datavault AI are available at https://dvlt.ai.
